Loading clinical trials...

Curcumin Supplement in Nonalcoholic Fatty Liver Patients | Clinical Trials | Clareo Health

COMPLETEDPHASE2/PHASE3

Curcumin Supplement in Nonalcoholic Fatty Liver Patients

The Effect of Curcumin Supplement on Metabolic Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Patients

NCT02908152•National Nutrition and Food Technology Institute

Summary

The purpose of this study is to investigate the effects of curcumin supplement on metabolic factors and hepatic fibrosis in nonalcoholic fatty liver patients with type 2 diabetes. Subjects will participate in 3 month, two group, randomized intervention, where one group (n=25) will take 1.5g/d curcumin and the other group (n=25) will take a placebo to compare differences in outcomes between the two groups.

Eligibility

Age

30 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient diagnosed with type 2 diabetes based on ADA definition or who only take oral antidiabetic drug;
•CAP score \>263.

Exclusion Criteria

•Taking any kind of antibiotics two weeks before recruitment;
•History of alcohol consumption;
•pregnancy or lactation;
•Professional athletes;
•Other liver disease (viral/etc);
•High dose synthetic estrogens, methotrexate, amiodarone, steroids, chloroquine, immunosuppressive drugs;
•A history of Cardiovascular disease;
•Renal disease, Celiac disease, Cirrhosis;
•History of Upper GI surgery;
•A history of hypothyroidism or Cushing's syndrome;
+5 more criteria

Locations (1)

NNFTRI

Tehran, Iran

Key Dates

Start Date

February 10, 2017

Primary Completion Date

July 10, 2017

Completion Date

October 10, 2017

Last Updated

September 29, 2020

Enrollment

ACTUAL participants

Conditions

Type 2 DiabetesNonalcoholic Fatty Liver

Interventions

curcumin

DIETARY_SUPPLEMENT

placebo

DIETARY_SUPPLEMENT

Feasibility of a Tailored Online Self-compassion Intervention

NCT07051005

Type 1 Diabetes MellitusType 2 Diabetes Mellitus (T2DM)

View study

RECRUITINGPHASE2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

NCT07296484

Type 2 DiabetesCortisol Excess

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: September 29, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Curcumin Supplement in Nonalcoholic Fatty Liver Patients

Inclusion Criteria

Exclusion Criteria

Feasibility of a Tailored Online Self-compassion Intervention

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

SGLT2i, Pioglitazone, and Ketone Production in T2D